Vanguard Group
PLX icon

Vanguard Group’s Protalix BioTherapeutics PLX Stock Holding History

Vanguard Group’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$879K Buy
488,552
+24,131
+5% +$49.3K ﹤0.01% 3813
2025
Q3 		$1.03M Sell
464,421
-20,377
-4% -$33.2K ﹤0.01% 3779
2025
Q2 		$718K Buy
+484,798
New +$992K ﹤0.01% 3839
2024
Q2 		– Sell
-330,047
Closed -$416K – 4435
2024
Q1 		$416K Buy
330,047
+27,361
+9% +$40.9K ﹤0.01% 4059
2023
Q4 		$539K Buy
302,686
+21,308
+8% +$33.1K ﹤0.01% 4006
2023
Q3 		$467K Buy
281,378
+51,041
+22% +$91.6K ﹤0.01% 4067
2023
Q2 		$461K Buy
+230,337
New +$549K ﹤0.01% 4143
2014
Q4 		– Sell
-11,196
Closed -$271K – 4050
2014
Q3 		$271K Buy
11,196
+2,025
+22% +$58.3K ﹤0.01% 3844
2014
Q2 		$335K Sell
9,171
-357
-4% -$14.4K ﹤0.01% 3765
2014
Q1 		$436K Buy
9,528
+1,894
+25% +$88.4K ﹤0.01% 3685
2013
Q4 		$297K Buy
7,634
+508
+7% +$21.4K ﹤0.01% 3708
2013
Q3 		$323K Buy
7,126
+565
+9% +$29K ﹤0.01% 3620
2013
Q2 		$322K Buy
+6,561
New +$348K ﹤0.01% 3569

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group's PLX Position: Q4 2025 in Review

Vanguard Group increased its Protalix BioTherapeutics (PLX) stake by 5.2% in Q4 2025, buying an estimated $49.3K and bringing the position to 488,552 shares worth $879K. The position accounts for ﹤0.01% of the portfolio, ranked #3813.

Vanguard Group first reported a position in PLX in Q2 2013 and has held it in 13 quarters since. The position peaked at $1.03M in Q3 2025. 83 funds tracked by Wall St. Rank hold PLX as of Q4 2025.

  • Vanguard Group held 488,552 shares of Protalix BioTherapeutics worth $879K as of Q4 2025.
  • Vanguard Group bought 24,131 Protalix BioTherapeutics shares in Q4 2025, an estimated $49.3K.
  • Protalix BioTherapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3813 holding.
  • Vanguard Group first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 13 quarters since.
  • Vanguard Group's Protalix BioTherapeutics position peaked at $1.03M in Q3 2025.
  • 83 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.